Primary plasma cell leukemia in the era of new drugs: Has something changed?

详细信息	查看全文 | 推荐本文 |

• 作者：Pellegrino Musto^a ; ¹ ; ^{p.musto@crob.it} ; ^{p.musto@tin.it}  ; [Author Vitae] ; Livio Pagano^b ; ¹ ; Maria Teresa Petrucci^c ; ¹ ; Fortunato Morabito^d ; ¹ ; Tommaso Caravita^e ; ¹ ; Francesco Di Raimondo^f ; ¹ ; Luca Baldini^g ; ¹ ; Patrizia Tosi^h ; ¹ ; Sara Bringhenⁱ ; ¹ ; Massimo Offidani^l ; Paola Omede&rsquo ; ⁱ ; ¹ ; Antonino Neri^g ; ¹ ; Fiorella D&rsquo ; Auria^a ; ¹ ; Giovanni Battista Bochicchio^j ; ¹ ; Michele Cavo^k ; ¹ ; Mario Boccadoroⁱ ; ¹ ; Antonio Palumboⁱ ; ¹
• 关键词：Plasma cell leukemia ; Myeloma ; Bortezomib ; Lenalidomide ; Thalidomide ; Stem cell transplantation
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2012
• 期刊代码：73_10408428
• 类别：med
• 出版时间：May, 2012
• 卷：82
• 期：2
• 页码：141-149
• 文件大小：147 K

摘要

Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disease is associated with a very poor prognosis, and unfortunately it has not significantly improved during the last three decades. Autologous stem cell transplantation is generally recommended in eligible patients, but survival in transplanted PPCL patients is significantly lower than that of multiple myeloma. Recent preliminary data indicate that new drugs, in particular lenalidomide and bortezomib, could significantly improve the clinical outcome of PPCL, increasing response rate and duration, as well as survival. In this review we report an updated literature analysis about the current therapeutic scenario of PPCL, with a particular focus on the use of novel agents.